首页> 外文期刊>Endocrine. >Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study
【24h】

Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study

机译:微波消融对初级乳头状微生物微癌的初步报告:185名患者可行性研究的大队列

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose To assess the safety and efficacy of microwave ablation (MWA) for primary papillary thyroid microcarcinoma (PTMC) with a large sample of 185 patients.Methods A total of 185 patients underwent MWA for 206 primary PTMC nodules. They received ultrasound follow-up at 1, 3, 6, and 12 months after MWA and every 6 months thereafter. Nodule volumes were calculated at each follow-up and compared with those before MWA. Additionally, the volume reduction rate (VRR) of the nodules was calculated. Patients' thyroid functions were tested before and 1 month after MWA.Results The mean follow-up time of the 185 patients was 20.7 ?8.8 months (range 12-36 months). During the follow-up period, the mean volume of the 206 nodules was 100.1 ?2.9 mm3 (range 3.6-423.9) before MWA, which decreased to 2.2 ?.6 mm3 (range 0-20.3 mm3) after MWA (P = 0.000). The mean VRR of the nodules was 98.65 ?3.60% after MWA (range 83.85-100%). One hundred and seventy four of 206 nodules (84.5%) were fully absorbed. Compared with the preoperative results, no significant variation in thyroid function was observed 1 month after MWA. Thirty-eight patients (20.5%) had different types of complications, ranging from minor to major. Five patients (2.7%) had hoarseness, 11 patients (5.9%) had bleeding, 21 patients (11.4%) had earache or toothache, and one patient had another lesion 1 month after MWA. Conclusions This preliminary study suggests that MWA is safe and effective in the treatment of primary PTMC and offers a new alternative for clinical treatment.
机译:目的,用于评估微波消融(MWA)对原发性乳头状甲状腺微癌(PTMC)的安全性和有效性,具有185例患者的大型样品。方法总共185名患者进行了206次初级PTMC结节。它们在MWA和此后每6个月后的1,3,6和12个月内接受超声后续随访。在每次随访中计算结节量,与MWA之前的那些进行比较。另外,计算结节的体积减少率(VRR)。患者的甲状腺功能在MWA后1个月进行测试。结果185名患者的平均随访时间为20.7?8.8个月(12-36个月)。在后续期间,MWA之前,206个结节的平均体积为100.1≤2.9mm3(范围3.6-423.9),在MWA(p = 0.000)之后减少到2.2Ω.6mm3(范围0-20.3 mm3) 。结节的平均VRR为98.65?MWA后3.60%(范围83.85-100%)。一百七十四个中的206个结节(84.5%)完全被吸收。与术前结果相比,MWA后1个月内未观察到甲状腺功能的显着变化。三十八名患者(20.5%)有不同类型的并发症,从次要到主要。五名患者(2.7%)具有嘶哑,11名患者(5.9%)出血,21例患者(11.4%)有耳痛或牙痛,一名患者在MWA后1个月患有另一名病变。结论这项初步研究表明,MWA在治疗原发性PTMC时是安全可有效的,并为临床治疗提供了一种新的替代方案。

著录项

  • 来源
    《Endocrine.》 |2019年第1期|共9页
  • 作者

    Deng-Ke Teng;

  • 作者单位

    Department of Ultrasound China-Japan Union Hospital of Jilin University Changchun Jilin 130000;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号